Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study
Clinical medicine. Oncology · 2008
DOI: 10.4137/cmo.s1027 ↗Abstrakt
Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m 2 , paclitaxel 155 mg/m 2 (both day 1) and capecitabine 665 mg/m 2 twice daily (days 1-14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
EUVIMED